- Home
- RARE vs ADEA Comparison
RARE vs ADEA Comparison
Compare RARE & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | ADEA |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | ADEA |
|---|---|---|
| Price | $23.40 | $19.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $73.11 | $22.50 |
| AVG Volume (30 Days) | ★ 4.0M | 975.2K |
| Earning Date | 02-12-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 1.01% |
| EPS Growth | N/A | ★ 75.65 |
| EPS | N/A | ★ 0.65 |
| Revenue | ★ $630,598,000.00 | $379,912,000.00 |
| Revenue This Year | $19.68 | $12.15 |
| Revenue Next Year | $19.44 | N/A |
| P/E Ratio | ★ N/A | $30.58 |
| Revenue Growth | ★ 20.63 | 10.53 |
| 52 Week Low | $18.41 | $10.59 |
| 52 Week High | $46.50 | $20.16 |
Technical Indicators
Market Signals| Indicator | RARE | ADEA |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 75.65 |
| Support Level | $22.00 | $18.65 |
| Resistance Level | $24.65 | $19.57 |
| Average True Range (ATR) | 1.28 | 0.69 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 44.59 | 88.09 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.